Will provide API and finished dosage manufacturing services
Aesica has formed a long-term strategic partnership with Mitovie Pharma through which it will provide clinical trial and commercial batch supply and formulation development services.
Mitovie originally chose R5 Pharmaceuticals (acquired by Aesica in June 2010) to develop a number of medicines in 2008 and following the successful delivery of the products, both companies have agreed to continue working together to develop further branded medicines and new medical devices, among other potential projects.
To date, Aesica’s Formulation Development team has produced Glysmag, which is used to treat low blood magnesium (hypomagnesaemia) in several pharmaceutical forms, Optidine, an antiseptic wash used in operating theatres, and Suptamid developed for SOS treatment in epilepsy.
The team is currently working on a new formulation of a patent-protected innovation in the field of anxiety, insomnia, sedation and severe, acute epileptic seizures.
Aesica will provide Mitovie with API and finished dosage manufacturing services, as well as formulation development expertise.
Paul Titley, md of Formulation Development at Aesica says: ‘We have worked with the team at Mitovie for almost three years and in that time have developed a number of novel concepts. To have been chosen by Mitovie as a long-term strategic partner is testament to the commitment of our team to provide fast, responsive bespoke solutions to development projects and to deliver the highest possible standards of service and quality.
‘As our working relationship evolves we look forward to developing new concepts, applications and devices and we are seeking to further extend our sterile formulation development capability to enhance our service offering in this particular market to Mitovie.’
Michael Hawthorne, chief executive of Mitovie Pharma, added: “We are very pleased with this development collaboration with Aesica as part of our commitment and drive to offer real medical solutions to clear medical challenges. We continue to be impressed by the skill and attitude of the team at Aesica. This partnership has already created innovative medicines that have helped patients today. We hope to see our partnership continue to grow as we identify new opportunities, such as sterile products and drug addiction, to work together for the benefit of our customers.’